Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Inclusion Criteria: * Histologic or cytologic diagnosis of primary tumor and conformed brain metastases by enhanced MRI or CT * the lesion number is no less than 3; or the tumor volume is no smaller than 6cc; or tumor diameter is no shorter than 3cm; or uncontrolled brain tumor after whole brain radiotherapy(WBRT); or the tumor is adjacent to essential structures of the brain, such as brain stem, optic chiasma, optic tract, etc. * KPS ≥60，or KPS ≥40 and the limitation of motion is simply caused by brain tumor that is adjacent to the motor function areas. * Age: 18-75 years old. * Adequate end-organ function: WBC≥4.0x109/L Neu ≥ 1.5x109/L Hemoglobin ≥ 110 g/L Platelets ≥100 x109/L Total bilirubin ≤ 1.5x ULN AST and ALT ≤ 1.5x ULN BUN and Cr: within the normal range Exclusion Criteria: * Other clinically significant diseases (e.g.myocardial infarction within the past 6 months, severe arrhythmia). * Unable or unwilling to comply with the study protocol. * The expected survival time is less than 3 months. * Patients who are anticipated in other clinical trials of brain metastases. * Patients who has been treated with SRT in other hospitals * Pregnant patients or female patients whose HCG is positive * Unsuitable to participate in study, that in the opinion of the treating physician.